Your browser doesn't support javascript.
loading
Surgery versus stereotactic body radiotherapy for clinical stage I non-small-cell lung cancer: propensity score-matching analysis including the ratio of ground glass nodules
Tomita, N; Shibamoto, Y; Okuda, K; Nakanishi, R; Osaga, S; Miyakawa, A.
Afiliación
  • Tomita, N; Nagoya City University Graduate School of Medical Sciences. Department of Radiology. Nagoya. Japan
  • Shibamoto, Y; Nagoya City University Graduate School of Medical Sciences. Department of Radiology. Nagoya. Japan
  • Okuda, K; Nagoya City University Graduate School of Medical Sciences. Department of Oncology, Immunology and Surgery. Nagoya. Japan
  • Nakanishi, R; Nagoya City University Graduate School of Medical Sciences. Department of Oncology, Immunology and Surgery. Nagoya. Japan
  • Osaga, S; Nagoya City University Graduate School of Medical Sciences. Clinical Research Management Center. Nagoya. Japan
  • Miyakawa, A; National Hospital Organization Nagoya Medical Center. Department of Radiation Oncology. Nagoya. Japan
Clin. transl. oncol. (Print) ; 23(3): 638-647, mar. 2021. graf
Article en En | IBECS | ID: ibc-220899
Biblioteca responsable: ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Purpose To investigate whether surgery and stereotactic body radiotherapy (SBRT) yield comparable outcomes for clinical stage (c-stage) I non-small-cell lung cancer (NSCLC), propensity score-matching (PSM) analysis was conducted. Methods This single-institutional retrospective study included patients who underwent surgery (n = 574) or SBRT (n = 182) between 2004 and 2014. PSM was performed based on tumor diameter, age, sex, performance status, forced expiratory volume, Charlson comorbidity index, and ground glass nodules (GGN) defined as cTis or cT1mi according to the 8th TNM classification. Results The median follow-up durations for the surgery and SBRT groups were 66 and 69 months, respectively. The multivariate analysis revealed that non-GGN was a significant factor for poorer overall survival (OS) and disease-free survival (DFS): hazard ratio (HR) 19.95% confidence interval (CI) 4.7–79, P < 0.001; and HR 28, 95% CI 6.9–110, P < 0.001, respectively. PSM identified 120 patients from each group. The 5-year OS and DFS rates of the surgery vs SBRT groups were 71% (95% CI 61–79) vs 64% (95% CI 54–72) (P = 0.41) and 63% (95% CI 53–72) vs 55% (95% CI 45–63) (P = 0.23) after PSM, respectively. Conclusion The PSM analyses including the ratio of GGN demonstrated that the OS and DFS for patients with c-stage I NSCLC in the surgery group were slightly superior to those for those in the SBRT group, although both survivals were not significantly different between the two therapeutic approaches (AU)
Asunto(s)
Palabras clave
Buscar en Google
Añadir a Mi BVS
Imprimir
XML

Colección: 06-national / ES Base de datos: IBECS Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Adult / Aged / Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2021 Tipo del documento: Article
Buscar en Google
Añadir a Mi BVS
Imprimir
XML

Colección: 06-national / ES Base de datos: IBECS Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Adult / Aged / Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2021 Tipo del documento: Article